Pfizer highlighted its latest dermatology portfolio at the eighth China International Import Expo (CIIE) held in Shanghai from Nov. 5 to 10, underscoring its commitment to advancing skin health and innovation in China's growing dermatology market.

Liu Jing, general manager of Pfizer China's Inflammation and Immunology business, speaks at the eighth China International Import Expo in Shanghai, Nov. 6, 2025. [Photo courtesy of Pfizer]

The company's Inflammation & Immunology unit presented Cibinqo (abrocitinib tablets) and Staquis (crisaborole ointment) for atopic dermatitis (AD), along with Litfulo (ritlecitinib capsules) for alopecia areata. The three treatments represent Pfizer's continued leadership in the research and application of JAK inhibitors, a class of medicines targeting inflammatory and immune pathways.

"This year marks Pfizer's seventh consecutive appearance at CIIE," said Liu Jing, general manager of Pfizer China's Inflammation and Immunology business, on Thursday. "Inflammation and immunology are strategic priorities for Pfizer. After more than 30 years of JAK research, we remain dedicated to improving care for Chinese patients living with inflammatory and immune diseases."

Liu said Pfizer continues to deepen real-world studies and collaborate across the healthcare ecosystem to promote evidence-based and standardized care. "We aim to build a patient-centered dermatology ecosystem and contribute to the goals of the Healthy China 2030 initiative," she added.

To enhance patient education and access to care, Pfizer has launched "AD Pedia Miniapp (AD Pedia)," China's first AI-powered specialized knowledge base for atopic dermatitis. The platform provides reliable information to help patients recognize symptoms, seek timely care, and manage their treatment journey more effectively.

"AD is a chronic and recurrent condition that requires long-term management," said Zhang Jianzhong, director of dermatology at Peking University People's Hospital. "AI tools like AD Pedia help improve consultation accuracy and follow-up efficiency, supporting standardized care."

Pfizer also expanded access to Litfulo, approved in China in 2023 for patients aged 12 and above with severe alopecia areata, an autoimmune disorder that causes hair loss. During the expo, the company announced partnerships with Chinese health care companies to build an integrated online and offline care platform for the condition, improving diagnosis, treatment, and follow-up services.

Through ongoing research, digital innovation, and multi-sector collaboration, Liu said Pfizer will continue to deliver science-driven solutions that improve skin health and quality of life for patients in China.